Literature DB >> 1354296

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.

P Fabris, C Betterle, A Floreani, N A Greggio, F de Lazzari, R Naccarato, M Chiaramonte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1354296     DOI： 10.1016/0140-6736(92)91744-s

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  36 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride.

Authors:  Shuhei Nishiguchi; Susumu Shiomi; Hiroko Kurooka; Yoshinori Iwata; Nobumitsu Sasaki; Akihiro Tamori; Daiki Habu; Tadashi Takeda; Joji Kawabe; Hironobu Ochi
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

3.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 4.  Diabetes mellitus during interferon therapy for chronic viral hepatitis.

Authors:  Ali Mofredj; Mehran Howaizi; Denis Grasset; Henri Licht; Sylvie Loison; Bruno Devergie; Renato Demontis; Jean-François Cadranel
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 5.  Dissecting the interaction between COVID-19 and diabetes mellitus.

Authors:  Ying Jie Chee; Seng Kiong Tan; Ester Yeoh
Journal:  J Diabetes Investig       Date:  2020-08-05       Impact factor: 4.232

Review 6.  Tissue-mediated control of immunopathology in coeliac disease.

Authors:  Bana Jabri; Ludvig M Sollid
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

7.  Rapidly reversible increase in insulin requirement with interferon.

Authors:  S Campbell; E H Mclaren; B J Danesh
Journal:  BMJ       Date:  1996-07-13

8.  Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis.

Authors:  A Imagawa; N Itoh; T Hanafusa; M Waguri; M Kuwajima; Y Matsuzawa
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

9.  Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C.

Authors:  P Falaschi; A Martocchia; R D'Urso; A Proietti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

Review 10.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.